A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Phase of Trial: Phase I/II
Latest Information Update: 13 Aug 2018
At a glance
- Drugs Erlotinib (Primary) ; Trametinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 02 Aug 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
- 02 Aug 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.
- 14 Mar 2017 New trial record